Medication Problem Prioritization

Why it matters

• A technically correct drug choice can still fail if the patient cannot open the bottle, remember the schedule, use the device, or safely self-monitor.
• BCPS stems often hide the real answer inside functional clues such as falls, missed refills, inability to manage insulin, or caregiver confusion.
• Acute cognitive change is a safety emergency because it changes adherence reliability, adverse-effect risk, and the urgency of medication review.
• Functional and cognitive findings frequently determine whether the best pharmacist recommendation is simplification, deprescribing, caregiver support, or urgent clarification of a new medication-related insult.

Key Terms & Must-Know Facts

Key terms

• ADLs: Basic self-care tasks such as bathing, dressing, toileting, transferring, continence, and feeding.
• IADLs: Higher-order tasks such as medication management, shopping, cooking, finances, transportation, and phone use.
• Delirium: Acute, fluctuating disturbance in attention and awareness; think urgent reversible cause.
• Dementia: Progressive cognitive decline interfering with independence; not typically abrupt.
• Mild cognitive impairment: Cognitive decline without full loss of independence; still high-risk for medication errors.
• Health literacy: Ability to obtain, process, and use health information.
• Medication self-management capacity: Ability to obtain, understand, organize, administer, and monitor medications correctly.
• Executive dysfunction: Impaired planning/organization; strongly linked to complex regimen failure.
• Beers Criteria: Framework identifying potentially inappropriate medications in older adults.
• Anticholinergic burden: Cumulative cognitive and functional adverse effects from anticholinergic drugs.
• Orthostatic hypotension: BP drop with standing that raises fall and syncope risk.
• Frailty: Reduced physiologic reserve; often increases sensitivity to adverse drug effects.
• Falls risk: Composite risk influenced by sedatives, BP lowering, neuropathy, gait impairment, and cognition.

Must-know facts

• Acute confusion plus fluctuating attention favors delirium, not chronic dementia.
• Medication management is an IADL; inability here may appear before loss of basic ADLs.
• Benzodiazepines, sedative hypnotics, strong anticholinergics, opioids, and some antihypertensives commonly worsen cognition or falls.
• A new functional decline after a medication change should be treated as a possible adverse drug effect until proven otherwise.
• For BCPS questions, the best answer is often regimen simplification rather than adding another drug.
• Insulin, anticoagulants, opioids, and sulfonylureas become higher-risk when cognition or dexterity is impaired.
• Caregiver reliability matters as much as patient reliability when assessing medication feasibility.
• Delirium workup and escalation come before nonurgent chronic optimization.
• Falls plus urinary urgency treatment often point to anticholinergic harm or overtreatment, not undertreatment.

flowchart TD
A[Medication problem noticed] --> B{Primary clue?}
B -->|Missed doses or device errors| C[Functional or IADL barrier]
B -->|Confusion, sedation, falls| D[Drug-related cognitive or safety effect]
B -->|Acute fluctuating attention| E[Possible delirium]
C --> F[Simplify regimen and assess caregiver support]
D --> G[Review high-risk drugs and recent changes]
E --> H[Urgent clarification and escalation]

See Fig 1 for the high-yield first-pass sort used in many exam stems.

Core content

1.1.2.1 Foundational framework: what to screen first when a regimen is failing

A. Explanation

The decision conflict is usually nonadherence versus inability versus toxicity. Students often overfocus on the drug name and miss the operational question: can this patient safely carry out the regimen as written? The single rule that resolves many stems is this: if the patient cannot perform medication-related IADLs or has an acute change in attention, the medication plan is not feasible until that barrier is addressed. WHY THIS IS TESTED: exam writers want to see whether you identify the true limiting factor before choosing a “better” drug.

Start with function because it converts abstract medication optimization into realistic execution. ADLs tell you how dependent the patient is overall; IADLs tell you whether the patient can manage medications. For pharmacists, the highest-yield IADLs are refill acquisition, pill organization, dose timing, glucose testing, injection technique, inhaler technique, and response to missed doses. Cognitive screening then asks whether the issue is chronic decline or acute delirium. Acute, fluctuating inattention changes the priority: you should recommend urgent clarification of causes and review recent drug exposures rather than simply counseling harder.

Choose functional assessment when the stem gives clues like unopened bottles, duplicate fills, inability to use an inhaler, or “forgets evening doses.” Reject the assumption that all missed doses equal motivation problems. Choose cognitive assessment when there is confusion, disorientation, fluctuating alertness, or caregiver concern. Reject routine outpatient simplification as the only answer if the mental status change is abrupt or dangerous.

See Fig 2 for the practical sequence: pattern first, then cause, then medication action.

B. Worked example

A 79-year-old woman with heart failure, type 2 diabetes, osteoarthritis, and macular degeneration is referred because her A1c increased from 7.4% to 9.1% while taking insulin glargine 24 units subcutaneously nightly, metformin ER 1000 mg orally twice daily, and empagliflozin 10 mg orally daily. She also takes furosemide, lisinopril, and diphenhydramine 50 mg nightly for sleep. Her serum creatinine is 1.0 mg/dL, BP 128/72 mm Hg, and she proudly reports never missing clinic visits. Her daughter mentions several half-full insulin pens in the refrigerator and that the patient “sometimes cannot read the pen numbers.”

Identify task: determine the most appropriate pharmacist focus before intensifying diabetes therapy. Extract key facts: rising A1c, vision impairment, duplicate unused pens, possible administration error, sedating anticholinergic exposure. Apply rule: when medication-related IADLs or device use are impaired, fix execution before escalating therapy. Eliminate distractors: adding prandial insulin is tempting because A1c is high, but it increases complexity and hypoglycemia risk. Increasing glargine may be reasonable only after confirming actual administration. Blaming motivation is unsupported; she attends visits and stores medications. Verify: the best action is to assess insulin administration technique and vision-related feasibility, simplify support, and review diphenhydramine because it can worsen cognition and nighttime safety.

C. Exam trap

D. Checkpoint

Question: A 76-year-old man with COPD, atrial fibrillation, and neuropathy uses tiotropium inhaler 2 inhalations daily, apixaban 5 mg orally twice daily, and gabapentin 300 mg orally three times daily. He reports “the inhaler never seems to help,” and his wife says he cannot remember whether he already took his evening apixaban. Which pharmacist assessment is most likely to clarify the governing problem?

1. A. Detailed dietary sodium review
   Tempting because COPD symptoms may be misattributed to fluid issues, but it does not address inhaler technique or dose duplication risk; wrong.
2. B. Evaluation of IADLs and medication self-management capacity
   Tempting because it feels broad, and it is correct because inhaler ineffectiveness plus uncertainty about anticoagulant dosing points to execution and organization barriers; right.
3. C. Immediate increase of tiotropium dose
   Tempting because persistent symptoms suggest undertreatment, but tiotropium failure may reflect device misuse rather than inadequate potency; wrong.
4. D. Change from apixaban to warfarin with INR monitoring
   Tempting because monitoring gives external oversight, but warfarin is more complex and does not solve the underlying self-management deficit; wrong.

1.1.2.2 Functional assessment in medication use: ADLs, IADLs, mobility, and dexterity

A. Explanation

The decision conflict here is keep the drug and adapt the delivery versus change the regimen because the task itself is unrealistic. The resolving rule is: when the patient cannot physically execute the required medication task, the best intervention is usually to reduce task burden, change formulation/device, or arrange support rather than choosing a pharmacologically “stronger” option. WHY THIS IS TESTED: many stems present poor control that is actually caused by inability to administer, measure, open, or coordinate a regimen.

ADLs indicate broad dependence, but IADLs are more tightly tied to outpatient medication safety. A patient may still bathe and feed independently yet be unable to manage insulin timing, inhaler assembly, or anticoagulant adherence. Functional medication red flags include arthritis preventing bottle opening, tremor interfering with syringe use, poor inspiratory force or coordination limiting inhaler technique, difficulty standing causing orthostasis-related falls after antihypertensive intensification, and swallowing problems that make the prescribed dosage form inappropriate.

Choose regimen simplification when once-daily alternatives, blister packaging, long-acting formulations, or caregiver-administered schedules reduce failure points. Reject medications that depend on precise timing, complex titration, difficult devices, or high-consequence self-monitoring if function is inadequate. For BCPS, the practical question is not “Can the patient understand this?” alone. It is “Can the patient physically and organizationally do this every day with acceptable risk?”

See Fig 3 when you need to translate a vague “nonadherence” stem into a specific physical barrier.

B. Worked example

A 73-year-old man with Parkinson disease, hypertension, BPH, and chronic kidney disease receives carbidopa/levodopa 25/100 mg orally four times daily, tamsulosin 0.4 mg orally nightly, amlodipine 10 mg orally daily, and oxybutynin ER 10 mg orally daily. His wife reports two falls in the last month after standing to urinate at night. He also has bothersome urgency. Clinic BP is 118/64 mm Hg seated; no serum abnormalities are notable today. A tempting clue is that the urgency makes escalation of bladder therapy look attractive.

Identify task: decide whether urinary symptom treatment should be intensified or reevaluated through function and fall risk. Extract key facts: nocturia, orthostasis-prone context, Parkinson mobility issues, falls, anticholinergic bladder drug, alpha-blocker at night. Apply rule: functional impairment plus fall history makes medications that worsen cognition, orthostasis, or mobility less acceptable. Eliminate distractors: increasing oxybutynin is tempting because urgency persists, but it may worsen cognition, constipation, and falls. Adding another antihypertensive is unsupported. Verify: the best pharmacist recommendation is to reassess the bladder regimen and fall-provoking drugs, not intensify the anticholinergic burden.

C. Exam trap

D. Checkpoint

Question: A 68-year-old woman with rheumatoid arthritis, diabetes, and asthma uses metformin ER 1000 mg orally twice daily, semaglutide 0.5 mg subcutaneously weekly, and budesonide/formoterol metered-dose inhaler 2 puffs twice daily. She reports worsening wheeze despite refill adherence. She cannot depress the inhaler canister reliably because of hand pain. Which recommendation is most appropriate?

1. A. Add tiotropium before assessing device-related barriers
   Tempting because symptoms remain uncontrolled, but escalation before fixing delivery may add cost without improving actual drug delivery; wrong.
2. B. Switch to a device or aid that better matches dexterity and reassess technique
   Tempting because it may seem less aggressive than adding medication, and it is correct because the key barrier is physical execution, not necessarily undertreatment; right.
3. C. Double the budesonide/formoterol dose immediately
   Tempting because inhaled corticosteroid step-up is familiar, but dose increase will not help if the patient cannot actuate the inhaler; wrong.
4. D. Discontinue semaglutide because nausea may worsen asthma control
   Tempting only if overreading unrelated adverse effects; it does not address the respiratory delivery problem; wrong.

1.1.2.3 Cognitive assessment: delirium versus chronic impairment and why the distinction changes pharmacist action

A. Explanation

The decision conflict is routine chronic support versus urgent medication-related safety evaluation. The single resolving rule is: acute onset with fluctuating attention should be treated as delirium until proven otherwise, and the pharmacist’s immediate role is to review recent medication changes, high-risk exposures, and safety-critical drugs. WHY THIS IS TESTED: exam stems often conceal delirium behind words like “more confused,” “sleepier,” or “not himself since admission.”

Delirium is typically abrupt and fluctuating; dementia is chronic and progressive. This distinction matters because acute cognitive change can be medication-induced or medication-worsened. Frequent culprits include anticholinergics, benzodiazepines, opioids, corticosteroids, certain antiinfectives, sedative-hypnotics, and polypharmacy after transitions of care. In hospital or postdischarge cases, a new mental status change should trigger a targeted medication reconciliation focused on new starts, dose escalations, renal accumulation, CNS depressant combinations, and withdrawal states.

Choose urgent clarification and escalation when the patient cannot sustain attention, is newly disoriented, or has fluctuating alertness. Reject a purely educational intervention in these cases. Choose chronic-support strategies when the cognitive decline is gradual and stable, such as pillbox support, caregiver training, deprescribing of low-value medications, and simplification. Reject the assumption that a normal serum creatinine or “normal labs today” excludes medication-induced delirium; cognitive toxicity is clinical and often multifactorial.

flowchart TD
A[Confusion reported] --> B{Onset}
B -->|Hours to days| C[Assess attention and fluctuation]
B -->|Months to years| D[Assess chronic impairment support needs]
C --> E{Fluctuating or inattentive?}
E -->|Yes| F[Possible delirium]
E -->|No| G[Consider other causes but still review meds]
F --> H[Check new drugs, accumulation, withdrawal, infection, pain]
D --> I[Caregiver support, simplification, adherence plan]

See Fig 4 when a stem tries to blur chronic memory issues with a new acute medication problem.

B. Worked example

An 82-year-old man with chronic kidney disease, benign prostatic hyperplasia, insomnia, and chronic low back pain was discharged 3 days ago on trimethoprim-sulfamethoxazole DS 1 tablet orally twice daily for a urinary infection, oxycodone 5 mg orally every 6 hours as needed, and his home diphenhydramine 25 mg nightly. He presents to clinic with his daughter, who says he was “sharp last week” but now naps during the day, is disorganized, and asks the same question repeatedly. His serum creatinine is slightly above baseline; potassium is mildly elevated. The tempting clue is the history of “memory problems sometimes,” which makes dementia sound possible.

Identify task: determine whether this is chronic decline or urgent medication-related cognitive change. Extract key facts: abrupt 3-day onset, fluctuating attention, new sedating drugs, renal vulnerability, anticholinergic exposure. Apply rule: acute fluctuating cognition favors delirium and requires medication review plus escalation. Eliminate distractors: starting a chronic dementia medication is inappropriate because the timeline is wrong. Reassurance is unsafe. Verify: the best pharmacist recommendation is urgent clarification of delirium triggers, review/hold likely contributors as appropriate, and communicate the medication safety concern to the care team.

C. Exam trap

D. Checkpoint

Question: A 71-year-old woman with CKD, depression, and neuropathy takes sertraline 100 mg orally daily, gabapentin 600 mg orally three times daily, trazodone 100 mg orally nightly, and was started on cyclobenzaprine 10 mg orally three times daily yesterday for muscle pain. Today her husband reports new confusion and unsteady gait. Which pharmacist recommendation is most appropriate?

1. A. Continue therapy and reassess in 1 week because sedation is expected early
   Tempting because some drowsiness does occur with CNS drugs, but acute confusion and gait instability raise immediate safety concerns; wrong.
2. B. Recommend urgent evaluation for possible medication-induced delirium and review recent CNS-active additions
   Tempting because it may feel like overreaction, but it is correct because abrupt change after adding a sedating anticholinergic-like agent is a red flag; right.
3. C. Increase sertraline because worsening mood can present as poor concentration
   Tempting because depression can impair concentration, but the abrupt onset after a new medication argues against mood as the primary cause; wrong.
4. D. Switch trazodone to zolpidem for cleaner sleep support
   Tempting because sleep medications are often changed in confusion cases, but adding another sedative ignores the acute trigger pattern; wrong.

1.1.2.4 Medication classes that worsen function, cognition, and falls

A. Explanation

The decision conflict is treat the original symptom versus avoid disproportionate harm in a vulnerable adult. The rule that resolves it is: in patients with impaired function, prior falls, or cognitive vulnerability, choose the option with the lowest sedation, anticholinergic burden, and orthostatic burden that still meets the therapeutic goal. WHY THIS IS TESTED: many board questions ask you to identify the one medication that turns an acceptable regimen into an unsafe one.

High-yield functional and cognitive offenders include benzodiazepines, nonbenzodiazepine hypnotics, first-generation antihistamines, tricyclic antidepressants, antimuscarinics for overactive bladder, skeletal muscle relaxants, opioids, and multidrug CNS depression. Antihypertensive intensification, diuretics timed poorly, and alpha-blockers may also worsen dizziness, nocturia, or falls. The exam challenge is comparative: not “is this drug ever used?” but “is this drug the least appropriate in this patient’s functional context?”

Choose alternatives that reduce central adverse effects or regimen burden. Reject “treating side effects with more drugs” if the original agent is the safer target. For example, nighttime diphenhydramine in an older adult with confusion is often the wrong answer even if insomnia is real; oxybutynin in a patient with falls and constipation is often the wrong answer even if urgency is real. Safety-first means tracing the adverse-effect mechanism back to the culprit drug class.

See Fig 5 for the classic culprit classes that appear repeatedly in geriatric pharmacotherapy stems.

B. Worked example

A 77-year-old woman with insomnia, neuropathy, overactive bladder, and hypertension takes zolpidem 10 mg orally nightly, gabapentin 300 mg orally three times daily, oxybutynin ER 10 mg orally daily, and hydrochlorothiazide 25 mg orally each morning. She had two nighttime falls this month. Sodium is 133 mEq/L, BP 110/62 mm Hg, and she reports dry mouth and constipation. A tempting clue is the mild hyponatremia, which may draw attention away from the medication pattern.

Identify task: determine the medication most important to target for functional safety. Extract key facts: falls at night, sedative-hypnotic, anticholinergic burden, borderline low BP, constipation, dry mouth. Apply rule: prioritize classes with strongest CNS or anticholinergic contribution and target modifiable medication-related harm first. Eliminate distractors: hydrochlorothiazide may contribute to nocturia and orthostasis, but the anticholinergic and hypnotic combination is more centrally concerning. Starting constipation therapy treats the consequence, not the cause. Verify: the answer centers on deprescribing or reassessing the fall-promoting sedative/anticholinergic regimen.

C. Exam trap

D. Checkpoint

Question: A 75-year-old man with diabetic neuropathy, BPH, chronic pain, and insomnia takes pregabalin 75 mg orally twice daily, oxycodone 5 mg orally every 8 hours as needed, tamsulosin 0.4 mg orally nightly, and doxylamine 25 mg orally nightly. He reports morning grogginess and one recent fall when getting out of bed. Which medication is the most appropriate first target for deprescribing discussion?

1. A. Pregabalin
   Tempting because it can cause dizziness, but the stem emphasizes a discretionary nighttime sedative with anticholinergic burden; wrong first target.
2. B. Oxycodone
   Tempting because opioids increase falls, but the drug is as-needed and the strongest nightly routine offender is elsewhere; wrong first target for this specific pattern.
3. C. Tamsulosin
   Tempting because nocturnal orthostasis matters, but the more avoidable sleep aid with anticholinergic burden is the clearer first target; wrong.
4. D. Doxylamine
   Tempting because OTC sleep aids are often overlooked, and it is correct because regular nighttime anticholinergic sedation best fits morning grogginess and fall risk; right.

1.1.2.5 Integrating findings into pharmacist recommendations: simplification, support, and monitoring

A. Explanation

The decision conflict is optimize disease metrics versus preserve safe medication use aligned with the patient’s actual capacity. The resolving rule is: after functional or cognitive impairment is identified, choose the least complex regimen that can reliably achieve the highest-priority therapeutic goals. WHY THIS IS TESTED: exam items reward you for matching regimen intensity to patient capacity, not for pursuing idealized guideline targets at any cost.

Practical pharmacist actions include deprescribing low-value or harmful medications, reducing dosing frequency, selecting easier dosage forms, synchronizing administration times, simplifying insulin plans, using teach-back, involving caregivers, and documenting clear monitoring parameters. The higher the consequence of a medication error, the lower the tolerance for unaided self-management. Thus insulin, anticoagulants, opioids, antiarrhythmics, and narrow-therapeutic-index medications demand special scrutiny.

Choose caregiver-supported or simplified regimens when the patient reliably benefits from them. Reject complex step-ups that depend on perfect timing or self-monitoring when that reliability is absent. In transitions of care, the pharmacist should clarify who owns the medication list, who fills it, and how follow-up will occur. This is also where upcoming topics connect: goals of care may appropriately de-intensify therapy, and renal function assessment may force additional dose simplification.

See Fig 6 for the integrated pharmacist action pathway most likely to produce the best exam answer.

B. Worked example

An 84-year-old woman with atrial fibrillation, heart failure, osteoarthritis, and mild cognitive impairment is discharged on apixaban 5 mg orally twice daily, furosemide 40 mg orally twice daily, metoprolol succinate 100 mg orally daily, acetaminophen 1000 mg orally three times daily, and newly prescribed tramadol 50 mg orally every 6 hours as needed. Her son visits three times weekly but does not live with her. She has previously mixed up morning and evening medications, and she now says, “I keep the blood thinner in my purse so I won’t forget it.” The distracting clue is stable vitals and an apparently normal discharge summary.

Identify task: decide the most appropriate pharmacist recommendation to improve safety after discharge. Extract key facts: high-risk anticoagulant, mild cognitive impairment, limited caregiver presence, evidence of disorganized storage, new opioid-like analgesic. Apply rule: when self-management of a high-harm medication is unreliable, simplify and support before accepting the regimen as written. Eliminate distractors: keeping all medications unchanged with routine counseling is inadequate. Adding another adherence app ignores cognition. Increasing home monitoring without changing the regimen burden may still fail. Verify: the best answer includes explicit anticoagulant organization support, regimen review for safer pain control, caregiver involvement, and clear follow-up monitoring.

C. Exam trap

D. Checkpoint

Question: A 78-year-old man with type 2 diabetes, coronary disease, and early cognitive decline takes insulin lispro 8 units subcutaneously with meals, insulin glargine 18 units nightly, aspirin 81 mg orally daily, and metoprolol tartrate 50 mg orally twice daily. His daughter can visit only on weekends. He often skips meals unpredictably and has had two recent hypoglycemic episodes. Which recommendation is most appropriate?

1. A. Increase mealtime lispro to improve A1c
   Tempting because insulin intensification can lower glucose, but unpredictable meal intake and cognitive impairment increase hypoglycemia risk; wrong.
2. B. Simplify the insulin regimen and reassess goals, adherence support, and monitoring plan
   Tempting because it may seem less aggressive than pursuing tighter control, and it is correct because safety and feasibility now govern the regimen choice; right.
3. C. Add glyburide to reduce injection burden
   Tempting because oral therapy seems simpler, but glyburide adds significant hypoglycemia risk in an older adult; wrong.
4. D. Continue the current regimen but move all doses to the morning
   Tempting because schedule consolidation sounds simpler, but it does not appropriately address meal-related insulin mismatch or hypoglycemia risk; wrong.

Exam Traps & Differentiators

• Most common wrong answer and why: Intensify disease therapy before assessing feasibility. This is tempting because the disease metric is abnormal, but the stem often gives a hidden clue that the patient cannot use the current regimen correctly.
• Looks similar but isn't: Chronic memory complaints are not the same as abrupt fluctuating attention. The former points to support planning; the latter points to delirium risk and urgent medication review.
• If the stem says “started yesterday,” “since discharge,” or “not himself today,” think recent medication change or accumulation.
• If the stem says unopened inhalers, extra insulin pens, or uncertain evening doses, think IADL failure rather than lack of efficacy.
• If the stem says falls, dry mouth, constipation, and sleep aid use, think anticholinergic or sedative burden.
• If the stem says poor vision, tremor, arthritis, or dysphagia, think device/formulation mismatch.
• If the stem says CKD plus new confusion on a renally cleared CNS-active drug, think dose accumulation; this links directly to the upcoming Renal Function Estimation topic.

flowchart LR
A[Abnormal outcome] --> B{What caused it?}
B -->|Disease truly uncontrolled| C[Intensify if safe]
B -->|Patient cannot execute regimen| D[Simplify or support]
B -->|Drug causing harm| E[Deprescribe or adjust]
B -->|Acute cognitive change| F[Urgent escalation and review]

Algorithm / Approach

Rapid Review

• Medication management → IADL, not ADL
• Acute fluctuating attention → think delirium, not routine dementia counseling
• Unused pens or inhalers → technique/execution failure before pharmacologic failure
• Falls plus dry mouth/constipation → think anticholinergic burden
• Nighttime grogginess with OTC sleep aid → first-generation antihistamine trap
• Unpredictable meals plus prandial insulin → simplify to reduce hypoglycemia risk
• High-risk drug plus uncertain dose timing → caregiver system change beats routine counseling
• Poor vision/tremor/arthritis → delivery mismatch more likely than “noncompliance”
• New confusion after discharge → review recent additions, duplications, and renal accumulation
• Orthostasis clues with BPH therapy → alpha-blocker safety review
• Chronic stable decline → support plan; abrupt change → urgent medication review
• Board-style best answer → address the limiting barrier, not just the disease marker

Self-check quiz

1. A 78-year-old woman with hypertension and osteoarthritis takes lisinopril 20 mg orally daily and acetaminophen 650 mg orally three times daily. Her daughter now fills her weekly pillbox because the patient can no longer manage refills, medication timing, or bill payment independently, although she still bathes and dresses herself. Which domain is most directly impaired?

1. A. ADLs
2. B. IADLs
3. C. Basic mobility only
4. D. Sensory function only

2. A 74-year-old man with allergic rhinitis, insomnia, and BPH takes tamsulosin 0.4 mg orally nightly and asks about an OTC sleep aid. Which option is most likely to worsen cognitive and anticholinergic burden?

1. A. Doxylamine 25 mg orally nightly
2. B. Melatonin 3 mg orally nightly
3. C. Ramelteon 8 mg orally nightly
4. D. Sleep hygiene counseling only

3. A 72-year-old woman with COPD, cataracts, and rheumatoid arthritis uses fluticasone/salmeterol metered-dose inhaler 2 puffs inhaled twice daily and albuterol inhaler 2 puffs every 4 hours as needed. She reports worsening dyspnea despite on-time refills. She cannot coordinate inhaler actuation because of hand pain, and a home pulse oximeter reading of 95% makes “stable disease” a tempting interpretation. Which is the most appropriate pharmacist recommendation?

1. A. Increase fluticasone/salmeterol strength immediately
2. B. Add tiotropium without reassessing device fit
3. C. Reassess technique and switch to a device strategy that matches her dexterity
4. D. Continue current therapy and recheck in 6 months

4. A 69-year-old man with CKD, neuropathy, and insomnia takes gabapentin 600 mg orally three times daily, trazodone 100 mg orally nightly, and was started on cyclobenzaprine 10 mg orally three times daily yesterday. His spouse reports new disorientation and wandering overnight. Temperature is normal, and his blood pressure is stable. Which pharmacist recommendation is most appropriate?

1. A. Continue therapy because the sedative effect should resolve after several days
2. B. Recommend urgent evaluation for possible medication-induced delirium
3. C. Increase trazodone because poor sleep likely explains the confusion
4. D. Add diphenhydramine for nighttime agitation

5. A 76-year-old woman with atrial fibrillation, diabetes, and mild cognitive impairment takes apixaban 5 mg orally twice daily, metformin ER 1000 mg orally twice daily, and insulin glargine 20 units subcutaneously nightly. She often cannot remember whether she took her evening apixaban, and her son visits only once weekly. Which is the most appropriate next pharmacist step?

1. A. Change apixaban to warfarin because INR monitoring will solve the problem
2. B. Intensify diabetes therapy because hyperglycemia is more urgent than anticoagulant organization
3. C. Implement a supervised medication organization strategy and reassess high-risk drug management
4. D. Continue the regimen because she can repeat instructions during counseling

6. An 83-year-old man with heart failure, CKD, BPH, and chronic pain takes furosemide 40 mg orally twice daily, tamsulosin 0.4 mg orally nightly, oxycodone 5 mg orally every 6 hours as needed, and diphenhydramine 25 mg orally nightly. He reports two nighttime falls, severe dry mouth, and morning confusion since starting the sleep aid 1 week ago. Which medication is the best first target for discontinuation recommendation?

1. A. Furosemide
2. B. Tamsulosin
3. C. Oxycodone
4. D. Diphenhydramine

7. A 79-year-old woman with type 2 diabetes, coronary disease, CKD, and early cognitive decline takes insulin lispro 10 units subcutaneously before meals, insulin glargine 26 units nightly, and metoprolol succinate 100 mg orally daily. She skips lunch often, has had two glucose readings below 60 mg/dL this week, and her neighbor occasionally reminds her to eat. A recent A1c of 8.4% makes intensification seem plausible. Which recommendation is most appropriate?

1. A. Increase lispro to 12 units before meals
2. B. Add glyburide 2.5 mg orally daily to improve A1c
3. C. Simplify the insulin regimen and reassess glycemic goals and support structure
4. D. Continue the current regimen because the A1c is not severely elevated

8. A 81-year-old woman with osteoarthritis, overactive bladder, depression, and insomnia takes sertraline 50 mg orally daily, oxybutynin ER 10 mg orally daily, gabapentin 300 mg orally three times daily, and zolpidem 10 mg orally nightly. She has constipation, dry mouth, and a new fall after waking to urinate at 2 AM. Which regimen feature most strongly explains the pattern and should drive the pharmacist’s recommendation?

1. A. Sertraline causing isolated orthostasis
2. B. Anticholinergic plus sedative burden from oxybutynin and zolpidem
3. C. Gabapentin alone because all falls on gabapentin require discontinuation
4. D. Untreated overactive bladder requiring a higher oxybutynin dose

Answer key

1. Question 1

Correct answer: B. IADLs

• A. ADLs: Tempting because the patient is older and needs help somewhere, but bathing and dressing remain intact; the single clue is loss of refill and bill management, which are IADLs, not ADLs. Source: functional assessment frameworks in geriatric pharmacotherapy texts and ACCP-style patient assessment principles.
• B. IADLs: Tempting because it directly matches medication management, and it is correct because handling refills, timing, and finances are classic instrumental tasks governing outpatient medication safety. Source: DiPiro and standard geriatric assessment models.
• C. Basic mobility only: Tempting if one assumes all independence problems stem from walking limitation, but the stem gives organization and finance deficits, not isolated gait impairment. Source: geriatric functional assessment literature.
• D. Sensory function only: Tempting because sensory loss can affect medication use, but no vision/hearing clue is given; the discriminator is inability to manage higher-order tasks. Source: standard functional domain definitions.

2. Question 2

Correct answer: A. Doxylamine 25 mg orally nightly

• A. Doxylamine: Tempting because it is a common OTC sleep option, and it is correct because first-generation antihistamines add anticholinergic burden, confusion risk, urinary retention risk, and falls risk, especially with BPH. Source: AGS Beers Criteria; AHFS Drug Information.
• B. Melatonin: Tempting because it is used for sleep, but it does not carry the same anticholinergic burden; the discriminator is drug class. Source: Beers Criteria comparison principles.
• C. Ramelteon: Tempting because it is also a sleep medication, but it is not the classic anticholinergic trap in older adults. Source: Lexicomp and geriatric sleep guidance.
• D. Sleep hygiene counseling only: Tempting because nonpharmacologic treatment is often preferred, but the question asks which option most likely worsens anticholinergic burden. Source: sleep management guidance.

3. Question 3

Correct answer: C. Reassess technique and switch to a device strategy that matches her dexterity

• A. Increase fluticasone/salmeterol strength immediately: Tempting because worsening dyspnea often leads to controller escalation, but the pharmacologic intensity is not the key issue when the patient cannot actuate the device. The single clue is hand pain preventing coordination. Source: inhaler technique guidance; DiPiro pulmonary therapeutics.
• B. Add tiotropium without reassessing device fit: Tempting because triple therapy may help COPD, but adding a second device can worsen the same execution barrier. The discriminator is inability to use the existing inhaler. Source: GOLD-informed medication use principles and device teaching standards.
• C. Reassess technique and switch to a device strategy that matches her dexterity: Correct because PK/PD benefit is impossible without delivery, and pharmacist-scope action is to optimize device selection and teach-back before escalation. Source: Lexicomp device counseling and guideline-based inhaler use recommendations.
• D. Continue current therapy and recheck in 6 months: Tempting because pulse oximetry is not alarming, but persistent symptoms with a known technique barrier require intervention now. The clue is demonstrated functional limitation. Source: COPD pharmacotherapy follow-up standards.

4. Question 4

Correct answer: B. Recommend urgent evaluation for possible medication-induced delirium

• A. Continue therapy because the sedative effect should resolve after several days: Tempting because mild drowsiness can occur early with CNS medications, but abrupt disorientation and wandering are safety red flags. The discriminator is acute onset after a new drug. Source: Beers Criteria; delirium medication safety literature.
• B. Recommend urgent evaluation for possible medication-induced delirium: Correct because acute fluctuating cognition after a new CNS-active medication in a CKD patient suggests drug-induced or drug-worsened delirium requiring prompt review. Source: geriatric delirium guidance; Lexicomp adverse-effect data.
• C. Increase trazodone because poor sleep likely explains the confusion: Tempting because insomnia and confusion may coexist, but more sedation worsens the likely mechanism. The clue is the recent addition of cyclobenzaprine. Source: AHFS; Beers Criteria.
• D. Add diphenhydramine for nighttime agitation: Tempting because it can sedate quickly, but anticholinergic burden can worsen delirium. The discriminator is acute confusion. Source: AGS Beers Criteria.

5. Question 5

Correct answer: C. Implement a supervised medication organization strategy and reassess high-risk drug management

• A. Change apixaban to warfarin because INR monitoring will solve the problem: Tempting because monitoring appears to add oversight, but warfarin is more complex and does not fix organization failure. The discriminator is unreliable dosing of a high-risk drug due to self-management limitations. Source: anticoagulation management principles; ACCP antithrombotic guidance.
• B. Intensify diabetes therapy because hyperglycemia is more urgent than anticoagulant organization: Tempting if focusing only on chronic disease metrics, but uncertain anticoagulant dosing creates immediate harm potential. Source: pharmacist prioritization and medication safety standards.
• C. Implement a supervised medication organization strategy and reassess high-risk drug management: Correct because the safest action addresses the execution barrier around a high-consequence medication and aligns the regimen with available support. Source: transitions-of-care and adherence support literature.
• D. Continue the regimen because she can repeat instructions during counseling: Tempting because in-clinic teach-back may look reassuring, but real-world uncertainty about doses is the decisive clue. Source: outpatient medication self-management frameworks.

6. Question 6

Correct answer: D. Diphenhydramine

• A. Furosemide: Tempting because nocturia and nighttime bathroom trips can contribute to falls, but the strongest new reversible driver of dry mouth and confusion is not the diuretic. The discriminator is symptom onset after the new sleep aid. Source: heart failure diuretic use guidance; Beers Criteria.
• B. Tamsulosin: Tempting because alpha-blockers can worsen orthostasis, but severe dry mouth and morning confusion are not its signature pattern. The clue is the recent addition of an anticholinergic sleep aid. Source: Lexicomp adverse-effect profiles.
• C. Oxycodone: Tempting because opioids increase falls, but it is as-needed and the cluster of anticholinergic symptoms points elsewhere as the best first target. Source: opioid safety guidance.
• D. Diphenhydramine: Correct because it is newly added, strongly anticholinergic, sedating, and best explains dry mouth, confusion, and nighttime fall risk. Source: AGS Beers Criteria; AHFS Drug Information.

7. Question 7

Correct answer: C. Simplify the insulin regimen and reassess glycemic goals and support structure

• A. Increase lispro to 12 units before meals: Tempting because the A1c remains above a typical goal, but skipped lunches and recent hypoglycemia make more prandial insulin unsafe. The discriminator is unpredictable meal intake. Source: diabetes management guidance; ADA Standards of Care.
• B. Add glyburide 2.5 mg orally daily to improve A1c: Tempting because it reduces injections, but glyburide is a poor older-adult choice because of prolonged hypoglycemia risk. The single eliminating fact is age with cognitive decline and hypoglycemia history. Source: ADA Standards; Beers Criteria.
• C. Simplify the insulin regimen and reassess glycemic goals and support structure: Correct because the practical and pharmacodynamic risk is excessive hypoglycemia from a complex meal-dependent regimen that the patient cannot execute reliably. Source: ADA Standards; DiPiro diabetes chapter.
• D. Continue the current regimen because the A1c is not severely elevated: Tempting because 8.4% is not extreme, but recent hypoglycemia already proves the regimen is unsafe as written. The clue is two glucose values below 60 mg/dL. Source: ADA hypoglycemia prevention guidance.

8. Question 8

Correct answer: B. Anticholinergic plus sedative burden from oxybutynin and zolpidem

• A. Sertraline causing isolated orthostasis: Tempting because SSRIs can have adverse effects and may contribute to falls in some patients, but dry mouth and constipation point more strongly to anticholinergic harm. The discriminator is the symptom cluster. Source: Lexicomp adverse-effect profiles.
• B. Anticholinergic plus sedative burden from oxybutynin and zolpidem: Correct because nighttime awakening plus sedation and anticholinergic effects creates a classic fall pattern. The single clue is the combination of constipation, dry mouth, and nocturnal fall. Source: Beers Criteria; OAB medication safety guidance.
• C. Gabapentin alone because all falls on gabapentin require discontinuation: Tempting because gabapentin can cause dizziness, but “all falls require discontinuation” is too absolute, and the stem gives stronger class-specific clues elsewhere. Source: neuropathic pain guidance and geriatric safety principles.
• D. Untreated overactive bladder requiring a higher oxybutynin dose: Tempting because the fall occurred during nighttime urination, but escalating the anticholinergic would worsen the likely mechanism. The key clue is existing anticholinergic adverse effects. Source: Beers Criteria; bladder pharmacotherapy references.